Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.80 |
| ▸ | RPS6KA1 | Q15418 | 15/20 | 0.80 |
| ▸ | AKT2 | P31751 | 14/20 | 0.80 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.80 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.78 |
| ▸ | GSK3B | P49841 | 5/20 | 0.78 |
| ▸ | CIT | O14578 | 1/20 | 0.78 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.78 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.78 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.78 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.78 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.78 |
| ▸ | ULK1 | O75385 | 1/20 | 0.78 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.78 |
| ▸ | SMC2 | O95347 | 1/20 | 0.78 |
| ▸ | LATS1 | O95835 | 1/20 | 0.78 |
| ▸ | PAK4 | O96013 | 1/20 | 0.78 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487654 | 1.00 | AKT1 (0.80) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13435150 | 1.00 | AKT1 (0.80) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Hydrochloric Acid SCHEMBL3487539 | 0.99 | AKT1 (0.79) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL18797652 | 0.89 | AKT1 (0.64) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13435151 | 0.89 | AKT1 (0.74) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3488371 | 0.89 | AKT1 (0.74) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487696 | 0.89 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL14536482 | 0.89 | AKT1 (0.62) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL14050840 | 0.89 | AKT1 (0.62) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Hydrochloric Acid SCHEMBL3487623 | 0.88 | AKT1 (0.73) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | claimed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | claimed |
| EP-1948188-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | claimed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-1948188-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | AKT1 829/4885ROCK1 2789/4885RPS6KA1 2404/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885ROCK1 478/4885RPS6KA1 127/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | AKT1 1236/4885ROCK1 1421/4885RPS6KA1 1411/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | AKT1 1216/4885ROCK1 1875/4885RPS6KA1 1310/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885ROCK1 478/4885RPS6KA1 127/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | AKT1 3945/4885ROCK1 2034/4885RPS6KA1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.